(Q28222549)

3

object named as

Dimitri P Mikhailidis

0 references

Efstathios D Pagourelias

4

object named as

Efstathios D Pagourelias

0 references

author name string

Vasilios G Athyros

1

0 references

Konstantinos Tziomalos

2

0 references

Anna I Kakafika

5

0 references

Athanasios Skaperdas

6

0 references

Apostolos Hatzitolios

7

0 references

Asterios Karagiannis

Expert Opinion on Pharmacotherapy

8

0 references

language of work or name

English

0 references

publication date

October 2007

0 references

published in

0 references

volume

8

0 references

issue

14

0 references

page(s)

2267-77

0 references

cites work

Dyslipidaemia, hypercoagulability and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517/14656566.8.14.2267

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.8.14.2267

Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Role of fibrates in reducing coronary risk: a UK Consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Niacin extended-release/lovastatin: combination therapy for lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Differential effects of nicotinic acid in subjects with different LDL subclass patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Extended-release niacin for modifying the lipoprotein profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Statin-fibrate combinations in patients with combined hyperlipedemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Targeting vascular risk in patients with metabolic syndrome but without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Treatment of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Current practice in the treatment of hyperlipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Lipids and atherosclerosis: clinical management of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

What is the most effective strategy for managing diabetic dyslipidaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Early vascular benefits of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Nicotinamide is a potent inhibitor of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Prevention and treatment of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Uric acid levels and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Antiatherothrombotic effects of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Analysis of antihypertensive effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

Benefits, challenges, and registerability of the polypill

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2267